Education
About Us
Working with TipRanks
Follow Us
SciSparc Ltd. (SPRC)
NASDAQ:SPRC
SPRC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.15 - $37.59
Previous CloseN/A
Volume2.49M
Average Volume (3M)13.02K
Market Cap
$3.53M
Enterprise Value$1.96M
Total Cash (Recent Filing)$2.06M
Total Debt (Recent Filing)$46.00K
Price to Earnings (P/E)―
Beta1.84
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.87
Shares Outstanding534,600
10 Day Avg. Volume22,936
30 Day Avg. Volume13,023
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.08
Price to Sales (P/S)0.00
P/FCF Ratio-0.68
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue0.21
Enterprise Value/Gross Profit3.88
Enterprise Value/Ebitda-0.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
SciSparc Ltd. News
PremiumCompany Announcements
SciSparc Ltd. Shareholders Approve Key Proposals at Annual Meeting
PremiumCompany Announcements
SciSparc Ltd. Adjourns Annual Meeting Due to Lack of Quorum
PremiumCompany Announcements
SciSparc Announces Reverse Share Split Effective July 3, 2025
PremiumCompany Announcements
SciSparc Ltd. Advances Merger with AutoMax Motors
PremiumCompany Announcements
SciSparc Unveils Japanese Patent for Novel Pain Relief CombinationOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
0.61% Other Institutional Investors
99.39% Public Companies and Individual Investors
SPRC FAQ
What was SciSparc Ltd.’s price range in the past 12 months?
SciSparc Ltd. lowest stock price was $4.15 and its highest was $37.59 in the past 12 months.
What is SciSparc Ltd.’s market cap?
SciSparc Ltd.’s market cap is $3.53M.
When is SciSparc Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were SciSparc Ltd.’s earnings last quarter?
SciSparc Ltd. released its earnings results on Dec 03, 2018. The company reported -$0.012 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.012.
Is SciSparc Ltd. overvalued?
According to Wall Street analysts SciSparc Ltd.’s price is currently Overvalued.
Does SciSparc Ltd. pay dividends?
SciSparc Ltd. does not currently pay dividends.
What is SciSparc Ltd.’s EPS estimate?
SciSparc Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SciSparc Ltd. have?
SciSparc Ltd. has 534,600 shares outstanding.
What happened to SciSparc Ltd.’s price movement after its last earnings report?
SciSparc Ltd. reported an EPS of -$0.012 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of SciSparc Ltd.?
Currently, no hedge funds are holding shares in SPRC
SciSparc Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.71%
12-Months-Change
Fundamentals
Return on Equity
-79.71%
Trailing 12-Months
Asset Growth
-7.47%
Trailing 12-Months
Company Description
SciSparc Ltd.
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Technical Analysis
Galmed Pharmaceuticals
―
InMed Pharmaceuticals
―
Enveric Biosciences
―
Artelo Biosciences
―
Tao Synergies
―